Abeona Therapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Abeona Therapeutics's estimated revenue is currently $5.3M per year.
- Abeona Therapeutics received $92.0M in venture funding in October 2017.
- Abeona Therapeutics's estimated revenue per employee is $57419
- Abeona Therapeutics's total funding is $12.9M.
- Abeona Therapeutics has 93 Employees.
- Abeona Therapeutics grew their employee count by 45% last year.
- Abeona Therapeutics currently has 1 job openings.
|James Bircher||SVP Quality and Technical Operations|
|Scott Santiamo||Director Corporate Communications|
|Jaime Fensterl||Associate Director, Program Management|
|Andre'a Andre'a Lucca||Vice President, Communications & Operations|
|Adam Davis||Director of Manufacturing|
|Magdalena Tyrpien||Director, Corporate Strategy|
|Carolyn Odom||Associate Director, Program Management|
|Christine Silverstein||Chief Financial Officer|
What Is Abeona Therapeutics?
Abeona Therapeutics Inc.(NASDAQ: $ABEO)is a leading clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|North Central B...||$38.6M||266||5%|
Abeona Therapeutics News
NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in ...
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies ...
NEW YORK and CLEVELAND, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in ...
Abeona Therapeutics Funding
Abeona Therapeutics Executive Hires
|2017-07-26||Juan Ruiz||Chief Medical Officer||Article|
|2018-04-03||Carsten Thiel||Chief Executive Officer||Article|
|2018-10-22||João Siffert||Head of Research and Development and Chief Medical Officer||Article|
Abeona Therapeutics New Location/Offices